Last reviewed · How we verify
LY007
At a glance
| Generic name | LY007 |
|---|---|
| Sponsor | Shanghai Longyao Biotechnology Inc., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Evaluation of LY007 Cell Injection for r/r B-NHL (PHASE1)
- An Evaluation of LY007 Cell Injection for r/r B-NHL (PHASE1)
- Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY007 CI brief — competitive landscape report
- LY007 updates RSS · CI watch RSS
- Shanghai Longyao Biotechnology Inc., Ltd. portfolio CI